In an effort to combat one of the most lethal forms of pediatric brain cancer, researchers at the UCLA Health Jonsson Comprehensive Cancer Center are launching a first-of-its-kind clinical trial to evaluate the safety and effectiveness of a cancer vaccine targeting H3 G34-mutant diffuse hemispheric glioma, a highly aggressive brain tumor that is typically found in adolescents and young adults.
Abivax presents first-half 2023 financial results – Biotech Investments
EQS-News: ABIVAX / Key word(s): Half Year Results Abivax presents first-half 2023 financial results 21.09.2023 / 18:00 CET/CEST The issuer is solely responsible for the content